{
    "clinical_study": {
        "@rank": "122725", 
        "arm_group": {
            "arm_group_label": "Birinapant with Conatumumab", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a dose escalation study in female subjects with relapsed ovarian cancer (including\n      epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer).\n      Approximately 30 to 40 subjects will be administered a combination of conatumumab and\n      birinapant.\n\n      In the initial dose-escalation stage of the study, adult female subjects will receive\n      conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to\n      determine the MTD of birinapant when administered with a fixed dose of conatumumab.\n\n      In safety expansion stage, adult female subjects will receive conatumumab in combination\n      with birinapant at the MTD of the combination."
        }, 
        "brief_title": "Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Relapsed Epithelial Ovarian Cancer", 
            "Relapsed Primary Peritoneal Cancer", 
            "Relapsed Fallopian Tube Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Peritoneal Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria-If subject:\n\n          -  Is a women who is at least 18 years of age.\n\n          -  Has a negative serum pregnancy test at screening for women of childbearing potential.\n\n          -  Pathologically confirmed ovarian cancer (epithelial ovarian cancer, primary\n             peritoneal cancer, or fallopian tube cancer) that are second line platinum resistant\n             or platinum sensitive subjects who are unable to receive further platinum based\n             therapy. Subjects may have had a maximum of 3 prior systemic chemotherapy regimens\n             (excluding hormonal therapies and investigational agents).\n\n          -  Has a performance status of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG)\n             scale.\n\n          -  Has a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)\n             1.1 criteria AND meet Gynecologic Cancer InterGroup (GCIG) CA 125 criteria.\n\n          -  Has a life expectancy of at least 3 months.\n\n          -  Has adequate liver, renal, pancreatic, coagulation and bone marrow function.\n\n          -  Has a Fc\u03b3RIIIa subtype of high/intermediate-affinity defined by polymorphism of V/V\n             or V/F and not F/F amino acids in receptors. (FOR EXPANSION PHASE ONLY)\n\n        Exclusion Criteria-If subject:\n\n          -  Has cancer that progresses within 6 months of completion of first line platinum-based\n             therapy.\n\n          -  Has symptomatic or uncontrolled brain metastases requiring current treatment (<8\n             weeks from last cranial radiation treatment or <4 weeks from last steroid treatment).\n\n          -  Has known intolerance to any of the study drugs or any of their excipients.\n\n          -  Has known or suspected diagnosis of human immunodeficiency virus (HIV) or chronic\n             active Hepatitis B or C.\n\n          -  Has uncontrolled hypertension defined as blood pressure >160/100 mmHg without\n             medication, or not controlled despite medications.\n\n          -  Has received systemic chemotherapy, hormonal therapy, immunotherapy, anti-tumor\n             necrosis factor (TNF) therapies, experimental or approved anticancer\n             proteins/antibodies therapy\n\n             \u226428 days before enrollment.\n\n          -  Has impaired cardiac function or clinically significant cardiac disease including the\n             following:\n\n               1. New York Heart Association Grade III or IV congestive heart failure.\n\n               2. Myocardial infarction within the last 12 months prior to dosing with birinapant.\n\n          -  Has a QT interval corrected for heart rate (QTcB) >480 msec (including subjects on\n             medication).  Subjects with a ventricular pacemaker for whom QT interval is not\n             measurable may be eligible.\n\n          -  Has a lack of recovery of prior adverse non-hematological events to Grade \u22641 severity\n             (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE]\n             v4.03) (except alopecia) due to therapy administered prior to the initiation of study\n             drug dosing.\n\n          -  Has any concurrent disease and/or medical condition that, in the opinion of the\n             Investigator, would prevent the subject's participation, render the subject at\n             excessive risk (including excessive risks due to the toxicity profile of the planned\n             combination chemotherapeutic regimen), or limit the subject's compliance with the\n             protocol's required evaluations.\n\n          -  Has a prior history of cranial nerve palsy.\n\n          -  Has autoimmune diseases or inflammatory diseases, for example, active rheumatoid\n             arthritis, active inflammatory bowel disease or any chronic inflammatory conditions.\n\n          -  Has pseudomyxoma, mesothelioma, unknown primary tumor, sarcoma, neuroendocrine\n             histology, clear cell or mucinous histology or subjects with borderline ovarian\n             cancer.\n\n          -  Requires concomitant chronic use of anti-TNF therapies, corticosteroids or\n             nonsteroidal anti- inflammatory drugs (NSAIDS). Intermittent use (7 or fewer days per\n             14 days) of corticosteroids as pre-medications is allowed."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940172", 
            "org_study_id": "TL32711-POC-0090-PTL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Birinapant with Conatumumab", 
                "description": "Dose Escalation:\nDose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks ); Dose Level (3a) - 17 mg/m2 (twice weekly for 4 weeks); OR Dose Level (3b) - 17 mg/m2 (twice weekly for 3 of 4 weeks)", 
                "intervention_name": "Birinapant", 
                "intervention_type": "Drug", 
                "other_name": "TL32711"
            }, 
            {
                "arm_group_label": "Birinapant with Conatumumab", 
                "description": "10 mg/kg IV on Day 1 and 15 of each cycle", 
                "intervention_name": "Conatumumab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "39720"
                    }, 
                    "name": "TetraLogic research site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Luis Obispo", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93401"
                    }, 
                    "name": "TetraLogic Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "TetraLogic Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "TetraLogic Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111"
                    }, 
                    "name": "TetraLogic Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "TetraLogic Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "TetraLogic Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75201"
                    }, 
                    "name": "TetraLogic Research Facility"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer", 
        "overall_contact": {
            "email": "susan.rippin@tetralogicpharma.com", 
            "last_name": "Susan Rippin", 
            "phone": "610-889-9900", 
            "phone_ext": "110"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determination of Maximum Tolerated Dose (MTD)", 
            "safety_issue": "Yes", 
            "time_frame": "28 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940172"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Clinical response as measured by RECIST (v1.1) criteria, CA 125 (GCIG criteria) and progression-free survival (PFS).", 
            "safety_issue": "No", 
            "time_frame": "Up to 4 months"
        }, 
        "source": "TetraLogic Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TetraLogic Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}